SE9901295D0 - Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea - Google Patents

Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea

Info

Publication number
SE9901295D0
SE9901295D0 SE9901295A SE9901295A SE9901295D0 SE 9901295 D0 SE9901295 D0 SE 9901295D0 SE 9901295 A SE9901295 A SE 9901295A SE 9901295 A SE9901295 A SE 9901295A SE 9901295 D0 SE9901295 D0 SE 9901295D0
Authority
SE
Sweden
Prior art keywords
patients
preventing
treating
cardiovascular complications
sleep
Prior art date
Application number
SE9901295A
Other languages
Swedish (sv)
Inventor
Jan Hedner
Ludger Grote
Original Assignee
Jan Hedner
Ludger Grote
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jan Hedner, Ludger Grote filed Critical Jan Hedner
Priority to SE9901295A priority Critical patent/SE9901295D0/en
Publication of SE9901295D0 publication Critical patent/SE9901295D0/en
Priority to PCT/SE2000/000688 priority patent/WO2000061144A1/en
Priority to AU43229/00A priority patent/AU4322900A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of preventing and/or treating sympathetically induced cardiovascular complications such as coronary artery disease, cardiac failure, myocardial infarction, and stroke, in patients with obstructive sleep apnea (OSA) disorder, comprises inhibiting the activation of the sympathoadrenergic system by administration of a pharmacologically effective amount of an I1-receptor agonist (IRA) prior to and/or during a period of sleep. Also disclosed is the use of an I1-imidazoline receptor agonist (IRA) for the diagnosis of such complications and for the manufacture of a medicament for preventing and/or treating sympathetically induced cardiovascular complications during sleep in patients with a sleep related breathing disorder.
SE9901295A 1999-04-13 1999-04-13 Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea SE9901295D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9901295A SE9901295D0 (en) 1999-04-13 1999-04-13 Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea
PCT/SE2000/000688 WO2000061144A1 (en) 1999-04-13 2000-04-11 Method and means for preventing, treating, and diagnosing cardiovascular complications in patients with obstructive sleep apnea
AU43229/00A AU4322900A (en) 1999-04-13 2000-04-11 Method and means for preventing, treating, and diagnosing cardiovascular complications in patients with obstructive sleep apnea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901295A SE9901295D0 (en) 1999-04-13 1999-04-13 Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea

Publications (1)

Publication Number Publication Date
SE9901295D0 true SE9901295D0 (en) 1999-04-13

Family

ID=20415182

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901295A SE9901295D0 (en) 1999-04-13 1999-04-13 Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea

Country Status (3)

Country Link
AU (1) AU4322900A (en)
SE (1) SE9901295D0 (en)
WO (1) WO2000061144A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
CA2637292A1 (en) * 2006-01-27 2007-08-16 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
KR20150055082A (en) 2010-03-26 2015-05-20 갈데르마 리써어치 앤드 디벨로프먼트 Improved methods and compositions for safe and effective treatment of erythema
AU2012324543B2 (en) 2011-10-19 2017-08-10 Galderma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

Also Published As

Publication number Publication date
WO2000061144A1 (en) 2000-10-19
AU4322900A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
Remmers Obstructive sleep apnea: a common disorder exacerbated by alcohol
JP2020033360A5 (en)
Naughton Pathophysiology and treatment of Cheyne-Stokes respiration
Biggs et al. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus: an in vivo microdialysis study
SE9702457D0 (en) screening
Antozzi et al. A short plasma exchange protocol is effective in severe myasthenia gravis
Gómez-Vázquez et al. Clinical analgesic efficacy and side effects of dexmedetomidine in the early postoperative period after arthroscopic knee surgery
CA2337422A1 (en) Preventing airway mucus production by administration of egf-r antagonists
WO2003089033A8 (en) Implantable drug delivery system responsive to intra-cardiac pressure
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
DE602005010213D1 (en) METHOD FOR THE TREATMENT AND DIAGNOSIS OF SLEEP PROBLEMS WITH ZONISAMIDE AND AGENTS FOR CARRYING OUT SAID METHOD
Albaladejo et al. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats
WO2007048353B1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
Djamilian et al. Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction
AU3258801A (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
NO20003313D0 (en) Therapeutic agents
SE9901295D0 (en) Methods and means for preventing, treating and diagnosing cardiovascular complications in patients with obstructive sleep apnea
Sackner et al. Hemodynamic effects of epinephrine and terbutaline in normal man
RU2007101288A (en) COMPOSITIONS AND METHODS OF APPLICATION OF DIMERIC DIGALLATES
GINSBURG et al. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine
Davies et al. Post carotid endarterectomy hypertension
SI9620036A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
BRPI0517166A (en) use of d-threo methylphenidate or a salt thereof
Misra et al. Sinus arrest caused by atenolol‐verapamil combination
Takashima et al. Intravenous infusion of amino acids in dogs attenuates hypothermia during anaesthesia and stimulates insulin secretion